Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

NCT03478488 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Neoplasms

Interventions

DRUG: KN035 plus Gemcitabine & oxaliplatin
DRUG: Gemcitabine & oxaliplatin

Sponsor

3D Medicines (Sichuan) Co., Ltd.